Novavax (NASDAQ:NVAX) has been downgraded from Overweight to Neutral in a statement by Piper Jaffray earlier today.
- Updated: September 16, 2016
Only yesterday Novavax (NASDAQ:NVAX) traded 0.36% higher at $8.34. NVAX’s 50-day moving average is $7.35 and its 200-day average is $6.24. With the last stock close up 33.70% relative to the 200-day average, compared to the S&P 500 Index which has decreased -0.01% over the same time. Trading volume was was up over the average, with 25,965,663 shares of NVAX changing hands over the typical 5,016,980 shares..
Piper Jaffray has downgraded Novavax(NASDAQ:NVAX) from Overweight to Neutral in a report released 9/16/2016.
Previously on 8/23/2016, Vetr Inc. released a statement for Novavax(NASDAQ:NVAX) raised the target price from $0.00 to $8.66. At the time, this suggested an upside of 0.17%.
Recent Performance Chart:
Also covering Novavax’s target price, a total of 8 brokerages have released a research note on the company. The one year target is $15.39 with five firms rating the stock a strong buy, three analysts rating the company a buy, 0 analysts rating the stock a hold, 0 rating the stock to underperform, and finally 0 analysts rating the company as sell.
Novavax has a 52 week low of $4.08 and a one-year high of $10.70. NVAX’s total market value is currently $0.0.
Brief Synopsis On Novavax (NASDAQ:NVAX)
Novavax, Inc. (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. Its product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). Its lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, and including Middle East respiratory syndrome (MERS).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.